代谢功能障碍相关脂肪性肝炎临床试验与竞争格局不断扩大，180多家公司瞄准新治疗方案 | DelveInsight

The market for Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatments is witnessing significant expansion, with more than 180 companies engaged in research and development. This surge in activity underscores the increasing attention and resources being directed towards finding effective therapies for MASH. The competitive landscape report details over 200 pipeline drugs, encompassing both approved and investigational treatments. It also provides analysis of clinical strategies, upcoming therapeutics, and commercial outlooks. This dynamic environment suggests a robust pipeline and potential for significant advancements in patient care for MASH.